William Rieflin
Chairman at NGM BIOPHARMACEUTICALS, INC.
Net worth: 850 604 $ as of 2024-03-30
William Rieflin active positions
| Companies | Position | Start | End |
|---|---|---|---|
| NGM BIOPHARMACEUTICALS, INC. | Chairman | 2018-08-31 | - |
| Director/Board Member | 2010-08-31 | 2018-08-31 | |
| Chief Executive Officer | 2010-08-31 | 2018-08-31 | |
| RAPT THERAPEUTICS, INC. | Independent Dir/Board Member | 2019-05-31 | - |
| Chairman | 2019-05-31 | - | |
| Director/Board Member | 2015-04-30 | 2019-05-31 | |
| LYELL IMMUNOPHARMA, INC. | Director/Board Member | 2020-04-30 | - |
| Independent Dir/Board Member | 2020-04-30 | - | |
Cumbre Pharmaceuticals, Inc.
 Cumbre Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cumbre Pharmaceuticals, Inc. discovers, develops, and markets anti-infective products for the treatment of serious and life-threatening infections, particularly caused by antibiotic resistant pathogens. Cumbre Pharmaceuticals was founded in 2001 and is headquartered in Dallas, TX | Director/Board Member | - | - |
Kallyope, Inc.
 Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | Director/Board Member | 2016-10-26 | - |
| Independent Dir/Board Member | 2016-10-26 | - | |
Lycia Therapeutics, Inc.
 Lycia Therapeutics, Inc. BiotechnologyHealth Technology Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA. | Director/Board Member | 2019-12-31 | - |
Career history of William Rieflin
Former positions of William Rieflin
| Companies | Position | Start | End |
|---|---|---|---|
| XENOPORT, INC. | Director/Board Member | 2010-09-16 | 2016-06-30 |
| Independent Dir/Board Member | 2004-08-31 | 2012-09-30 | |
| President | 2004-08-31 | 2010-08-25 | |
| Corporate Secretary | 2004-08-31 | 2009-06-04 | |
| ANACOR PHARMACEUTICALS INC | Director/Board Member | 2011-03-31 | 2016-06-23 |
| Independent Dir/Board Member | 2011-03-31 | 2016-06-23 | |
Flexus Biosciences, Inc.
 Flexus Biosciences, Inc. BiotechnologyHealth Technology Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA. | Director/Board Member | - | 2014-12-31 |
| ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░░ ░░░░░░░░ ░░░░░░ ░░░░░ | ░░░░░ ░ ░░░░░░░░░ | - | - |
| ░░░░░░ ░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░░ ░░░░░░░ | - | - | |
| ░░░░░░░░░ ░░░░░░░░░ | - | - |
Training of William Rieflin
| Cornell University | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
| Stanford Law School | Graduate Degree |
Statistics
International
| United States | 17 |
Operational
| Director/Board Member | 9 |
| Independent Dir/Board Member | 5 |
| Corporate Secretary | 3 |
Sectoral
| Health Technology | 11 |
| Consumer Services | 4 |
| Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| NGM BIOPHARMACEUTICALS, INC. | Health Technology |
| RAPT THERAPEUTICS, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Private companies | 10 |
|---|---|
AMSCO International, Inc.
 AMSCO International, Inc. Medical SpecialtiesHealth Technology Part of STERIS Plc (Ireland), AMSCO International, Inc. makes infection control and decontamination products. The private company is based in Pittsburgh, PA. AMSCO International was acquired by STERIS Corp. on May 13, 1996 for $619.50 million. | Health Technology |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Cumbre Pharmaceuticals, Inc.
Cumbre Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cumbre Pharmaceuticals, Inc. discovers, develops, and markets anti-infective products for the treatment of serious and life-threatening infections, particularly caused by antibiotic resistant pathogens. Cumbre Pharmaceuticals was founded in 2001 and is headquartered in Dallas, TX | Health Technology |
| American Hospital Supply Corp. | Health Technology |
| Sidley & Austin | Commercial Services |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Flexus Biosciences, Inc.
Flexus Biosciences, Inc. BiotechnologyHealth Technology Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA. | Health Technology |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | Health Services |
Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. BiotechnologyHealth Technology Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- William Rieflin
- Experience